Gene Circuit Therapeutics Market Report 2025

The gene circuit therapeutics market size has grown exponentially in recent years. It will grow from $1.5 billion in 2024 to $1.84 billion in 2025 at a compound annual growth rate (CAGR) of 22.5%. The growth during the historic period is driven by the expanding study of quorum sensing-based gene circuits, increased use of epigenetic regulatory modules, development of bio-computational therapeutic frameworks, incorporation of optogenetic control systems, and rising interest in non-coding RNA-mediated circuit designs.

The gene circuit therapeutics market size is expected to see exponential growth in the next few years. It will grow to $4.12 billion in 2029 at a compound annual growth rate (CAGR) of 22.3%. The projected growth in the forecast period is supported by broader adoption of cell-based therapies, growing investment in synthetic biology research, rising demand for personalized medicine, increased government funding for gene therapy development, and advancements in gene editing technologies. Key trends in this period include progress in programmable gene network therapies, refined cell-specific gene circuit modulation, innovations in synthetic feedback loop design, integration of computational modeling for circuit optimization, and development of controllable therapeutic gene switches.

The rising demand for personalized medicine is set to drive the expansion of the gene circuit therapeutics market. Personalized medicine involves customizing treatment based on the individual genetic, biomarker, or molecular profile of each patient. The increased demand for personalized approaches is largely fueled by advancements in genomics and synthetic biology, which enable more accurate targeting of diseases and better therapeutic outcomes. Gene circuit therapeutics play a key role by engineering cells and microorganisms with programmable logic that allows them to sense, compute, and respond to specific disease conditions, leading to more effective and individualized treatments. For example, NHS England reported that the total number of personalized genomic tests reached 65,884 in 2024, reflecting a 14% increase from 2023, which underscores the growing demand for personalized medicine. As a result, this demand is driving the growth of the gene circuit therapeutics market.

Key players in the gene circuit therapeutics market are focusing on developing programmable gene circuits that enable more precise disease targeting, controlled therapeutic responses, and enhanced treatment safety. These programmable circuits are genetic networks designed from DNA, RNA, and regulatory proteins, which mimic logical operations in cells to detect biological signals, process them, and produce specific outputs. For instance, in May 2023, Synlogic, Inc., a US-based biotechnology company, presented new data at the Synthetic Biology Engineering, Evolution & Design (SEED) Conference on SYNB1353, a Synthetic Biotic drug candidate for homocystinuria (HCU). This drug uses genetically engineered probiotic bacteria with metabolic gene circuits to consume methionine and reduce toxic homocysteine levels. This application of programmable circuits shows their potential not only in oncology but also in treating rare metabolic disorders, highlighting their ability to create targeted, durable, and patient-friendly treatments.

In June 2022, Senti Biosciences Inc., a US-based company specializing in next-generation cell and gene therapies using gene circuits, merged with Dynamics Special Purpose Corp. in a $156.5 million business deal. The merger was aimed at strengthening Senti’s capital position, advancing its proprietary gene circuit platform, and accelerating the development of its off-the-shelf CAR-NK cell therapies targeting cancer. Dynamics Special Purpose Corp. was a US-based special purpose acquisition company focused on healthcare and life sciences platforms, including synthetic biology and innovative drug discovery technologies.

Major players in the gene circuit therapeutics market are GenScript Biotech, Agilent Technologies, Cellectis S.A., CRISPR Therapeutics, Beam Therapeutics, Twist Bioscience, Ginkgo Bioworks, Sangamo Therapeutics, Senti Biosciences, Editas Medicine, BlueRock Therapeutics, Synthego Corporation, Manus Bio, Strand Therapeutics, Dyno Therapeutics, Obsidian Therapeutics, Rubius Therapeutics, Precigen Inc., Aurealis Therapeutics, Synlogic Inc., Azalea Therapeutics.

North America was the largest region in the gene circuit therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gene circuit therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gene circuit therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Gene circuit therapeutics refers to medical treatments that employ engineered gene networks within cells to regulate their behavior. These gene circuits function as miniature biological programs, activating or deactivating genes in response to specific signals. Such therapeutics enable more precise disease management by allowing immune cells to target cancer or by safely controlling other cellular functions.

The primary product categories in gene circuit therapeutics include synthetic gene circuits, programmable cell therapies, gene editing tools, and related products. Synthetic gene circuits consist of engineered networks of artificial genetic elements that interact to regulate gene expression, influence cellular behavior, and control the production or modification of DNA and RNA for targeted therapies. Progress in this field is driving the creation of highly precise treatments for complex medical conditions. Core technologies include CRISPR, TALEN, zinc finger nucleases, and similar tools. Applications span oncology, rare diseases, infectious diseases, regenerative medicine, and more, and are employed by pharmaceutical and biotech companies, research and academic institutions, hospitals, and clinics.

The gene circuit therapeutics market research report is one of a series of new reports that provides gene circuit therapeutics market statistics, including gene circuit therapeutics industry global market size, regional shares, competitors with the gene circuit therapeutics market share, gene circuit therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the gene circuit therapeutics industry. This gene circuit therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gene circuit therapeutics market consists of revenues earned by entities by providing services such as cellular pathway modeling, gene circuit testing and validation, therapeutic gene delivery consulting, immune cell engineering support, and bioinformatics analysis for circuit optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene circuit therapeutics market includes sales of gene delivery vectors, inducible gene switches, synthetic promoters, engineered regulatory proteins, and cell-based assay kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.